<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899467</url>
  </required_header>
  <id_info>
    <org_study_id>GT0918-US-1002</org_study_id>
    <nct_id>NCT03899467</nct_id>
  </id_info>
  <brief_title>the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer</brief_title>
  <official_title>An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Kintor Pharmaceutical Inc,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Kintor Pharmaceutical Inc,</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, expanded/phase II study in subjects with metastatic&#xD;
      castrate resistant prostate cancer (mCRPC) who progressed after either abiraterone or&#xD;
      enzalutamide.&#xD;
&#xD;
      The objective of the study is to evaluate the safety and tolerability of proxalutamide and&#xD;
      determine the RP2D for Ph III and/or other confirming studies.&#xD;
&#xD;
      Subjects will be randomized into the 2 treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, randomized, expanded/phase II study in subjects with metastatic&#xD;
      castrate resistant prostate cancer (mCRPC) who progressed after either abiraterone or&#xD;
      enzalutamide. All subjects will be randomized to take 400 mg or 500 mg of GT0918 by oral&#xD;
      administration once daily on an empty stomach (2-3 hours after a meal) for initial treatment&#xD;
      of 6 months. Randomization of subjects will be stratified by prior therapy (abiraterone or&#xD;
      enzalutamide).&#xD;
&#xD;
      Subjects will continue treatment with GT0918 (proxalutamide) at their assigned dose on an&#xD;
      empty stomach until disease progression, intolerable toxicities (AEs), or withdrawn consent.&#xD;
      A post-treatment period of 4 weeks will commence that concludes with an end-of-study visit.&#xD;
&#xD;
      Disease progression will be assessed by three methods over the duration of the study.&#xD;
      Subjects will be assessed for biochemical (PSA) progression measured monthly, as well as&#xD;
      radiographic progression by CT scan or/and bone progression by radionuclide bone scan every&#xD;
      12-weeks. Progressive disease will be considered on the occurrence of the first assessed&#xD;
      progression event. Subjects with PSA progression only may continue the study until&#xD;
      radiographic or bone progression at the discretion of the Investigator and with agreement by&#xD;
      the sponsor or their authorized medical monitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recommended Phase 2 dose (RP2D)</measure>
    <time_frame>6 month</time_frame>
    <description>determine the RP2D for Ph III and/or other confirming studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Toxicity of proxalutamide</measure>
    <time_frame>6 month</time_frame>
    <description>Only adverse events that are possibly, probably or definitely related to study drug are reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt;50% PSA suppression</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate proportion of subjects with a &gt; 50% PSA suppression at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of radiographic disease progression</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>To evaluate percentage of radiographic disease progression at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiographic and bone progression time</measure>
    <time_frame>6 month</time_frame>
    <description>To evaluate time to radiographic and bone progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to PSA progression</measure>
    <time_frame>6 month</time_frame>
    <description>To evaluate the time to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory biomarkers: cell free circulating tumor DNA (ct-DNA)/RNA (ct-RNA)</measure>
    <time_frame>6 month</time_frame>
    <description>To identify exploratory biomarkers to characterize androgen receptor (AR) inhibition and/or down-regulation by proxalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory biomarkers: Circulating tumor cells (CTC)</measure>
    <time_frame>6 months</time_frame>
    <description>anti-tumor activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</condition>
  <arm_group>
    <arm_group_label>Arm 1: biological dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg/day of proxalutamide&#xD;
Group 1: Post enzalutamide failure&#xD;
Group 2: Post abiraterone failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: MTD dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg/day of proxalutamide&#xD;
Group 1: Post enzalutamide failure&#xD;
Group 2: Post abiraterone failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GT0918</intervention_name>
    <description>anti-tumor activity</description>
    <arm_group_label>Arm 1: biological dose group</arm_group_label>
    <arm_group_label>Arm 2: MTD dose group</arm_group_label>
    <other_name>proxalutamide</other_name>
    <other_name>androgen receptor antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Signed informed consent obtained prior to any study-related procedure being performed.&#xD;
&#xD;
          2. Subjects at least 18 years of age or older at the time of consent.&#xD;
&#xD;
          3. Subjects with histologically confirmed metastatic castrate resistant prostate cancer&#xD;
             (mCRPC) who progressed after abiraterone or enzalutamide.&#xD;
&#xD;
          4. Ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone&#xD;
             (LHRH) &quot;super-agonist&quot; or antagonist, or bilateral orchiectomy and serum testosterone&#xD;
             level &lt; 50 ng/dL (&lt; 0.5 ng/mL, &lt; 1.7 nmol/L) at screening.&#xD;
&#xD;
          5. Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging&#xD;
             (MRI) or bone scan.&#xD;
&#xD;
          6. Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but&#xD;
             not both. However, if either of these 2 drugs was used less than 3 months due to&#xD;
             toxicity, the patient is eligible. One line of chemotherapy is eligible. Progressive&#xD;
             disease is defined by 1 or more of the following criteria:&#xD;
&#xD;
               1. Subjects with a rising prostate specific antigen (PSA) value &gt; 2 ng/mL in at&#xD;
                  least 2 measurements, at least 1 week apart. If the confirmatory PSA value is&#xD;
                  less than the screening PSA value, then an additional test for the rising PSA is&#xD;
                  required to document progression.&#xD;
&#xD;
               2. Subjects with measurable disease, progression defined by Response Evaluation&#xD;
                  Criteria in Solid Tumors (RECIST) 1.1 criteria&#xD;
&#xD;
               3. Subjects with metastatic bone disease, progression defined by 2 or more new&#xD;
                  lesions in a radionuclide bone scan.&#xD;
&#xD;
          7. ECOG performance status of 0-1&#xD;
&#xD;
          8. Screening blood counts of the following:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1500/μL&#xD;
&#xD;
               2. Platelets ≥ 100,000/μL&#xD;
&#xD;
               3. Hemoglobin &gt; 9 g/dL (if asymptomatic).&#xD;
&#xD;
          9. Screening chemistry values of the following:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper&#xD;
                  limit of the normal reference range (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤ 2 × ULN&#xD;
&#xD;
               3. Creatinine ≤ 1.5 × ULN&#xD;
&#xD;
               4. Albumin &gt; 2.8 g/dL.&#xD;
&#xD;
         10. At screening, life expectancy of at least 6 months.&#xD;
&#xD;
         11. Subjects whose partners are women of childbearing potential (WOCBP) must use an&#xD;
             adequate method of birth control while on study drug and for at least 3 months after&#xD;
             discontinuation of study drug.&#xD;
&#xD;
         12. Subject is willing and able to comply with all protocol required visits and&#xD;
             assessments.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Discontinuation of enzalutamide or abiraterone less than 3 weeks prior to the start of&#xD;
             study medication.&#xD;
&#xD;
          2. Prior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less&#xD;
             than 3 weeks prior to the start of study medication&#xD;
&#xD;
          3. Prior chemotherapies more than 1 line.&#xD;
&#xD;
          4. Ongoing acute treatment-related toxicity associated with a previous therapy greater&#xD;
             than grade 1 except for grade 2 alopecia or neuropathy.&#xD;
&#xD;
          5. History of impaired adrenal gland function (e.g., Addison's disease, Cushing's&#xD;
             syndrome).&#xD;
&#xD;
          6. Known gastrointestinal disease or condition that affects the absorption of&#xD;
             proxalutamide.&#xD;
&#xD;
          7. History of congestive heart failure New York Heart Association (NYHA) class III or IV&#xD;
             or uncontrolled hypertension at screening.&#xD;
&#xD;
          8. History or family history of long QT syndrome, or ECG corrected QT interval equal to&#xD;
             and over 500 ms (CTCAE grade 2) at baseline.&#xD;
&#xD;
          9. History of other malignancy within the previous 3 years, except basal cell or squamous&#xD;
             cell carcinoma, or non-muscle invasive bladder cancer.&#xD;
&#xD;
         10. Use of systemic glucocorticoid (e.g., prednisone, dexamethasone) within 14 days prior&#xD;
             to the start of study medication. Inhaled or topical steroids are allowed.&#xD;
&#xD;
         11. Co-administration of CYP3A4 ligands that serve as substrates or induce or inhibit the&#xD;
             enzyme (See Appendix 4 for the list of medications).&#xD;
&#xD;
         12. Prior use of any herbal products known to decrease PSA levels (e.g., PC-SPES or saw&#xD;
             palmetto) within 30 days prior to the start of study medication.&#xD;
&#xD;
         13. Major surgery within 30 days prior to the start of study medication.&#xD;
&#xD;
         14. Blood transfusion (including blood products) within 1 week of screening.&#xD;
&#xD;
         15. Serious persistent infection within 14 days prior to the start of study medication.&#xD;
&#xD;
         16. Serious concurrent medical condition including CNS disorders.&#xD;
&#xD;
         17. Previous history of difficulty swallowing capsules.&#xD;
&#xD;
         18. Known hypersensitivity to GT0918 or its excipients (See Appendix 5 for drug details).&#xD;
&#xD;
         19. Any condition that, in the opinion of the investigator, would impair the subject's&#xD;
             ability to comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phoebe Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Kintor Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phoebe Zhang, PhD</last_name>
    <phone>+1-984-208-1255</phone>
    <email>pzhang@kintor.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <email>research2@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Adkisson</last_name>
      <phone>502-629-2500</phone>
      <email>pamela.adkisson@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Chandler Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Welk</last_name>
      <phone>443-471-5740</phone>
      <email>kwelk@chesuro.com</email>
    </contact>
    <investigator>
      <last_name>Richard Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G U Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Rosso, BSN, RN</last_name>
      <phone>402-697-2229</phone>
      <email>erosso@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Luke T Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Mianulli, BSN,RN</last_name>
      <phone>702-952-3834</phone>
      <email>Karyn.Mianulli@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Vogelzang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Cancer &amp; Blood Specialists</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen M Vicuña</last_name>
      <phone>718-732-4078</phone>
      <email>cvicuna@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>Fabio Volterra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Cancer &amp; Blood Specialists</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Marx, MBA, MS, RT</last_name>
      <phone>631-675-5143</phone>
      <email>dmarx@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>Zulfiqar Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <phone>484-998-8315</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Hetzel</last_name>
      <phone>864-242-2762</phone>
      <email>Joanne.Hetzel@PrismaHealth.org</email>
    </contact>
    <investigator>
      <last_name>Britt Bolemon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gena Rangel</last_name>
      <phone>972-566-3058</phone>
      <email>grangel@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>Ashley Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Androgen Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

